[Sweden / Australia / UK] Harms of morphine for chronic breathlessness in relation to dose, duration and titration phase

[Sweden / Australia / UK] Harms of morphine for chronic breathlessness in relation to dose, duration and titration phase
Journal of Pain and Symptom Management; by Magnus Ekström, Fatima Alameri, Sungwon Chang, Diana Ferreira, Miriam J Johnson, David C Currow; 6/25
In people with COPD and severe chronic breathlessness, the risk of adverse events was highest during the first week of treatment in a dose-related fashion but did not differ by titration phase or by dose of once-daily SR morphine between 8 and 32 mg/day.